Belgium· BE-AMP-SAM554257-00

Beovu 120 mg/ml

A brolucizumab product containing brolucizumab, registered in Belgium by Novartis Europharm. The same ATC class is registered in 13 of our 19 countries.

ATC S01LA06

Checked against FAMHP / AFMPS (Belgium) on

Informational only — not a medical device.

SOURCE REGISTER · BEFAMHP / AFMPS (Belgium)normalisedBeovu 120 mg/mlATCS01LA06REGISTER NO.BE-AMP-SAM554257-00PACKS LISTED2CHECKEDSeptember 26, 2026

Where it is registered

Brolucizumab is registered in 13 of 19 countries.

Countries holding a registration under ATC S01LA06 (brolucizumab), each read from that country’s own register.

  • This record: Belgium, from FAMHP / AFMPS (Belgium)
  • 8 of them publish a price we can compare per daily dose

Brolucizumab · ATC S01LA06

13 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

FAMHP / AFMPS (Belgium)
Active substance
Brolucizumab
Manufacturer
Novartis Europharm
Country
Belgium (BE)
ATC code
S01LA06
ATC class
Brolucizumab
Defined daily dose
0.0357 DE, IVT
Reimbursed
Not published by this register
Source register
FAMHP / AFMPS (Belgium)
Last checked
September 26, 2026

Packs & prices · 2

  • be_apb
    4175592
  • be_apb
    7738677

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Brolucizumab in 14 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All brolucizumab products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Beovu
  • Liechtenstein · Beovu
  • Norway · Beovu

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/6278a5ae-8b90-4dc3-9cee-4a9b6c43fe39
GET /v1/drugs/6278a5ae-8b90-4dc3-9cee-4a9b6c43fe39?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Solution for injection in pre-filled syringe",
  "source": "afmps",
  "status": "AUTHORIZED",
  "name_en": "Beovu 120 mg/ml",
  "name_fr": "Beovu 120 mg/ml",
  "name_nl": "Beovu 120 mg/ml",
  "amp_code": "SAM554257-00",
  "strengths": [
    "120.0000"
  ],
  "pack_count": 1,
  "substances": [
    "Brolucizumab",
    "Sucrose",
    "Polysorbate 80"
  ],
  "medicine_type": "ALLOPATHIC",
  "atc_description": "Brolucizumab",
  "authorisation_numbers": [
    "EU/1/19/1417/001"
  ]
}

See everything about brolucizumab.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.